Infection Risk in Patients with Complement-Mediated Neurological Disorders Receiving Eculizumab: Findings from Two Phase 3 Studies and Their Extensions in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+NMOSD) and Acetylcholine-Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis (AChR plus gMG)

被引：1
|
作者：
Levine, Todd [1 ]
Mantegazza, Renato [2 ]
Oreja-Guevara, Celia [3 ]
Carrillo-Infante, Cynthia [4 ]
Kaprielian, Roger [5 ]
Shang, Shulian [4 ]
Yountz, Marcus [4 ]
Howard, James [6 ]
机构：
[1] Phoenix Neurol Associates, Phoenix, AZ USA
[2] Fdn IRCCS Ist Neurol Carlo Besta, Via Celoria 11, I-20133 Milan, Italy
[3] Hosp Univ Clin San Carlos, Madrid, Spain
[4] Alex Pharmaceut, Boston, MA USA
[5] Alex Pharmaceut, Vaughan, ON, Canada
[6] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27515 USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1829
引用
收藏
页数：4
相关论文
共 21 条
  • [1] Diffuse Gonococcal Infection in a Patient with Treatment Refractory Acetylcholine Receptor Antibody-Positive (AChR plus ) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab
    Katyal, Nakul
    Nirola, Latika
    Narula, Naureen
    Govindarajan, Raghav
    ANNALS OF NEUROLOGY, 2021, 90 : S212 - S212
  • [2] Benefit of eculizumab for a broad range of patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from prevent
    Fujihara, K.
    Berthele, A.
    Kim, H. J.
    Levy, M.
    Nakashima, I.
    Oreja-Guevara, C.
    Palace, J.
    Pittock, S.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Miller, L.
    Tanvir, I.
    Armstrong, R.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 447 - 448
  • [3] Safety and Effectiveness of Eculizumab in Japanese Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+NMOSD): Interim Analysis of a Post-Marketing Surveillance Study
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP25 - NP25
  • [4] Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study
    Fujihara, Kazuo
    Berthele, Achim
    Kim, Ho Jin
    Levy, Michael
    Nakashima, Ichiro
    Oreja-Guevara, Celia
    Palace, Jacqueline
    Pittock, Sean J.
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Pace, Amy
    Yountz, Marcus
    Miller, Larisa
    Tanvir, Imran
    Armstrong, Roisin
    Wingerchuk, Dean M.
    NEUROLOGY, 2020, 94 (15)
  • [5] Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study
    Berthele, Achim
    Pittock, Sean J.
    Fujihara, Kazuo
    Kim, Ho Jin
    Levy, Michael
    Palace, Jacqueline
    Nakashima, Ichiro
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Shang, Shulian
    Yountz, Marcus
    Armstrong, Roisin
    Wingerchuk, Dean M.
    NEUROLOGY, 2020, 94 (15)
  • [6] Diffuse Gonococcal Infection (DGI) in a Patient with Treatment-Refractory Acetylcholine Receptor Antibody-Positive (AChR plus ) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab
    Katyal, Nakul
    Nirola, Latika
    Narula, Naureen
    Govindarajan, Raghav
    CASE REPORTS IN NEUROLOGICAL MEDICINE, 2021, 2021
  • [7] Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study
    Palace, J.
    Pittock, S. J.
    Berthele, A.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 737 - 738
  • [8] Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study
    Berthele, A.
    Pittock, S. J.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 294 - 295
  • [9] Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
    Pittock, S.
    Berthele, A.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Palace, J.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 289 - 290
  • [10] Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study
    Kim, H. J.
    Pittock, S. J.
    Berthele, A.
    Fujihara, K.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 288 - 289
123